Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Edgewise Therapeutics ( (EWTX) ) is now available.
On November 10, 2025, Edgewise Therapeutics announced the appointment of Michael Nofi as Chief Financial Officer, succeeding Michael Carruthers who is retiring. Mr. Nofi, with over 30 years of experience in the life sciences sector, joins Edgewise at a crucial time as the company advances its late-stage clinical development and prepares for commercialization, bringing expertise in financial operations and strategic growth.
The most recent analyst rating on (EWTX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Edgewise Therapeutics stock, see the EWTX Stock Forecast page.
Spark’s Take on EWTX Stock
According to Spark, TipRanks’ AI Analyst, EWTX is a Underperform.
Edgewise Therapeutics’ overall score reflects significant risks due to its pre-revenue stage and increasing losses. Positive corporate events, including substantial fundraising and promising trial results, offer growth potential. However, the bearish technical indicators and valuation challenges highlight the stock’s high-risk profile typical of early-stage biotech companies.
To see Spark’s full report on EWTX stock, click here.
More about Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company is advancing its expertise in muscle physiology to create new treatments, with key products including sevasemten, EDG-7500, and EDG-15400, which are in various stages of clinical development.
Average Trading Volume: 876,764
Technical Sentiment Signal: Buy
Current Market Cap: $1.82B
For an in-depth examination of EWTX stock, go to TipRanks’ Overview page.